Home LiteratureArticle Details
PMID: 11172041 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

p53 accumulation, defective cell proliferation, and early embryonic lethality in mice lacking tsg101.

Ruland J, Sirard C, Elia A, MacPherson D, Wakeham A, Li L, de la Pompa JL, Cohen SN, Mak TW

Abstract

Functional inactivation of the tumor susceptibility gene tsg101 in NIH 3T3 fibroblasts results in cellular transformation and the ability to form metastatic tumors in nude mice. The N-terminal region of tsg101 protein is structurally similar to the catalytic domain of ubiquitin-conjugating enzymes, suggesting a potential role of tsg101 in ubiquitin-mediated protein degradation. The C-terminal domain of TSG101 can function as a repressor of transcription. To investigate the physiological function of tsg101, we generated a null mutation of the mouse gene by gene targeting. Homozygous tsg101-/- embryos fail to develop past day 6.5 of embryogenesis (E6.5), are reduced in size, and do not form mesoderm. Mutant embryos show a decrease in cellular proliferation in vivo and in vitro but no increase in apoptosis. Although levels of p53 transcripts were not affected in tsg101-/- embryos, p53 protein accumulated dramatically, implying altered posttranscriptional control of p53. In addition, transcription of the p53 effector, cyclin-dependent kinase inhibitor p21(WAF-1/CIP-1), was increased 5- to 10-fold, whereas activation of MDM2 transcription secondary to p53 elevation was not observed. Introduction of a p53 null mutation into tsg101-/- embryos rescued the gastrulation defect and prolonged survival until E8.5. These results demonstrate that tsg101 is essential for the proliferative burst before the onset of gastrulation and establish a functional connection between tsg101 and the p53 pathway in vivo.

MeSH Terms
Animals Cell Division Cyclin-Dependent Kinase Inhibitor p21 Cyclins/metabolism DNA-Binding Proteins/genetics,physiology Embryo Loss/metabolism Embryonic and Fetal Development Endoderm/metabolism Endosomal Sorting Complexes Required for Transport Gene Expression Gene Targeting Mesoderm/metabolism Mice Mice, Inbred C57BL Mice, Knockout Nuclear Proteins Proto-Oncogene Proteins/metabolism Proto-Oncogene Proteins c-mdm2 Transcription Factors/genetics,physiology Tumor Suppressor Protein p53/genetics,metabolism
Chemicals
Cdkn1a protein, mouse Cyclin-Dependent Kinase Inhibitor p21 Cyclins DNA-Binding Proteins Endosomal Sorting Complexes Required for Transport Nuclear Proteins Proto-Oncogene Proteins Transcription Factors Tsg101 protein Tumor Suppressor Protein p53 Mdm2 protein, mouse Proto-Oncogene Proteins c-mdm2
Authors & Affiliations
9 authors, click to expand affiliations / ORCID
Ruland J
Amgen Institute, 620 University Avenue, Toronto, ON, Canada M5G 2C1.
Sirard C
Elia A
MacPherson D
Wakeham A
Li L
de la Pompa J L
Cohen S N
Mak T W
References (27)
27 references, click to expand
  1. The ARF/p53 pathway.
    Curr Opin Genet Dev. 2000 Feb;10(1):94-9 PMID: 10679383
  2. Differential regulation of glucocorticoid receptor transcriptional activation via AF-1-associated proteins.
    EMBO J. 1999 Oct 1;18(19):5380-8 PMID: 10508170
  3. A TSG101/MDM2 regulatory loop modulates MDM2 degradation and MDM2/p53 feedback control.
    Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1619-24 PMID: 11172000
  4. A mouse model of greig cephalopolysyndactyly syndrome: the extra-toesJ mutation contains an intragenic deletion of the Gli3 gene.
    Nat Genet. 1993 Mar;3(3):241-6 PMID: 8387379
  5. The Brachyury gene encodes a novel DNA binding protein.
    EMBO J. 1993 Dec;12(12):4898-9 PMID: 8223498
  6. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
    Cell. 1993 Nov 19;75(4):805-16 PMID: 8242751
  7. WAF1, a potential mediator of p53 tumor suppression.
    Cell. 1993 Nov 19;75(4):817-25 PMID: 8242752
  8. Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit.
    Nature. 1993 Dec 16;366(6456):707-10 PMID: 8259216
  9. Expression of transcription factor HNF-4 in the extraembryonic endoderm, gut, and nephrogenic tissue of the developing mouse embryo: HNF-4 is a marker for primary endoderm in the implanting blastocyst.
    Proc Natl Acad Sci U S A. 1994 Aug 2;91(16):7598-602 PMID: 8052626
  10. Tumor spectrum analysis in p53-mutant mice.
    Curr Biol. 1994 Jan 1;4(1):1-7 PMID: 7922305
  11. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53.
    Nature. 1995 Nov 9;378(6553):203-6 PMID: 7477326
  12. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53.
    Nature. 1995 Nov 9;378(6553):206-8 PMID: 7477327
  13. Tsg101: a novel tumor susceptibility gene isolated by controlled homozygous functional knockout of allelic loci in mammalian cells.
    Cell. 1996 May 3;85(3):319-29 PMID: 8616888
  14. The tumor suppressor gene Brca1 is required for embryonic cellular proliferation in the mouse.
    Cell. 1996 Jun 28;85(7):1009-23 PMID: 8674108
  15. The TSG101 tumor susceptibility gene is located in chromosome 11 band p15 and is mutated in human breast cancer.
    Cell. 1997 Jan 10;88(1):143-54 PMID: 9019400
  16. Transgenic mice with p53-responsive lacZ: p53 activity varies dramatically during normal development and determines radiation and drug sensitivity in vivo.
    EMBO J. 1997 Mar 17;16(6):1391-400 PMID: 9135154
  17. Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos.
    Genes Dev. 1997 May 15;11(10):1226-41 PMID: 9171368
  18. Brca2 is required for embryonic cellular proliferation in the mouse.
    Genes Dev. 1997 May 15;11(10):1242-52 PMID: 9171369
  19. Partial rescue of Brca1 (5-6) early embryonic lethality by p53 or p21 null mutation.
    Nat Genet. 1997 Jul;16(3):298-302 PMID: 9207798
  20. Absence of rearrangements in the tumour susceptibility gene TSG101 in human breast cancer.
    Nat Genet. 1997 Aug;16(4):332-3 PMID: 9241265
  21. The breast cancer gene product TSG101: a regulator of ubiquitination?
    J Mol Med (Berl). 1997 Jul;75(7):467-9 PMID: 9253709
  22. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways.
    Cell. 1998 Mar 20;92(6):725-34 PMID: 9529249
  23. A putative tumor suppressor, TSG101, acts as a transcriptional suppressor through its coiled-coil domain.
    Biochem Biophys Res Commun. 1998 Apr 28;245(3):900-5 PMID: 9588212
  24. Signaling to p53: breaking the MDM2-p53 circuit.
    Cell. 1998 Oct 2;95(1):5-8 PMID: 9778240
  25. Genomic architecture and transcriptional activation of the mouse and human tumor susceptibility gene TSG101: common types of shorter transcripts are true alternative splice variants.
    Oncogene. 1998 Nov 26;17(21):2761-70 PMID: 9840940
  26. Tumor susceptibility gene 101 protein represses androgen receptor transactivation and interacts with p300.
    Cancer. 1999 Aug 15;86(4):689-96 PMID: 10440698
  27. SUMO-1 modification of Mdm2 prevents its self-ubiquitination and increases Mdm2 ability to ubiquitinate p53.
    Cell. 2000 Jun 23;101(7):753-62 PMID: 10892746
Article Info
Journal
Proceedings of the National Academy of Sciences of the United States of America
Abbr.
Proc Natl Acad Sci U S A
ISSN
0027-8424
Published
2001-02-13
Pages
1859-64
Language
English
Region
United States
NLM ID
7505876
PMCID
PMC29347
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com